Tianchen Bio Completes Over RMB 200 Million Series C Financing to Accelerate Commercialization of Core Pipeline and Global Innovation

VCBeat has learned that recently, an innovative biopharmaceutical companyLongBio Biopharmaceuticals (Suzhou) Co., Ltd. (hereinafter referred to as "LongBio")Announced the completion of over RMB 200 million in Series C financing. This round of financing was led byHLC,Existing ShareholdersQiming Venture PartnersCo-led investment,Linchuang Lanwan Fund, Beida Fund, Zhenmai FundCo-investment, existing shareholdersSanyi Capital, Shanzheng Innovationcontinued intensification.

The financing proceeds will be primarily allocated to Phase III clinical trials and subsequent commercialization preparations for the core pipeline asset, the next-generation anti-IgE antibody LP-003, as well as to Phase II clinical development of LP-005, a first-in-class complement bifunctional antibody, across multiple indications, further solidifying LongBio’s innovative leadership in the fields of allergy and complement-mediated diseases.

Over the past year, LongBio has successively completed its Series B2, Series B3, and Series C financing rounds, with a cumulative amount exceeding RMB 300 million, highlighting strong recognition from the capital market of its technological prowess and commercial potential. At the 2025 Future Healthcare Industry Summit held in May this year, LongBio was successfully selected for the “2025 Top 100 Future Healthcare Companies · Top 100 Chinese Innovative Pharmaceuticals and Biological Products List.”

As the most advanced investigational anti-IgE antibody in global development, LP-003 has entered Phase III clinical trials for allergic rhinitis, with submission of a New Drug Application (NDA)/Biologics License Application (BLA) expected in early 2026. Phase III clinical trials for its second indication, chronic urticaria, are also scheduled to commence in 2026. Furthermore, Phase II clinical trials for additional indications, including allergic asthma and food allergies, are currently underway, which will continue to expand the product’s commercial value in the future.

Based on head-to-head clinical results against omalizumab, LP-003 demonstrates advantages including rapid onset, superior efficacy, long-acting duration, sustained improvement, lower dosage, and enhanced safety compared to omalizumab (which achieved global sales of $4.4 billion in 2024). LP-003 is poised to become a “Best-in-class” drug in this field, unlocking an allergic disease market valued at over $10 billion.

LP-005 is the world’s first bifunctional antibody fusion protein capable of simultaneously inhibiting all three complement pathways, and it has demonstrated significant efficacy in Phase II clinical trials for paroxysmal nocturnal hemoglobinuria (PNH). Clinical studies targeting complement-mediated kidney diseases (such as IgA nephropathy and C3 glomerulopathy) and other indications are scheduled to commence in 2025.

Leveraging its innovative "one drug, multiple targets" mechanism, LP-005 has the potential to fill therapeutic gaps across multiple unmet clinical needs.

Amidst the booming global market for allergy and complement therapeutics, LongBio is accelerating its journey toward becoming a global leader in biopharmaceuticals, driven by breakthrough technological innovations and underpinned by a deeply diversified pipeline and differentiated competitive advantages. The company is committed to setting industry benchmarks in the fields of allergic diseases and complement-mediated disorders. By continuously pioneering innovative treatment solutions, LongBio aims to deliver breakthrough therapies with greater clinical value and accessibility to patients worldwide, thereby reshaping the international competitive landscape in these therapeutic areas.

Lead Investor of This RoundHLCstated: “LongBio’s differentiated layout in the fields of allergy and complement possesses significant clinical value and market potential. This round of financing is not only a critical step toward the commercialization of its first innovative drug, but will also accelerate the globalization of its pipeline, providing patients with better treatment options.”

Linchuang Lanwan Fundstated: “Leveraging its leading position in the fields of allergy and complement, LongBio is targeting a blue-ocean market worth tens of billions of dollars. Its core team combines expertise in blockbuster drug development with global execution capabilities. This round of financing will accelerate the commercialization and international expansion of its core pipeline, strengthening the global competitiveness of China’s original innovative drugs.”

Beida Fundstated: “We are delighted to participate in LongBio’s new round of financing. The company is dedicated to the research and development of innovative drugs in the fields of allergy and complement, with its core product LP-003 demonstrating significant clinical potential and the promise to address multiple unmet clinical needs. Beida Biopharmaceutical Industry Fund is optimistic about its potential to benefit patients through innovation and looks forward to creating greater value.”